Discover key facts about the healthcare market in the UK and learn about our latest market research for our pharmaceutical, medical device, and healthcare sector clients.
Key facts about the UK health market:
Funding in the UK healthcare system
The UK has a universal public healthcare system. The majority of health needs, including hospital, physician, and mental health care, are funded through general taxation. A small proportion of the UK’s population carries voluntary supplemental insurance.
Health technology assessment in the UK
If NICE recommends the use of a pharmaceutical treatment, funding must be made in available within 3 months for patients to access treatment on the NHS throughout England and Wales. The National Institute for Health and Care Excellence (NICE) sets guidelines for clinically effective treatments and appraises new health technologies (both pharmaceutical and medical devices) for their efficacy and cost effectiveness. Similarly, medical devices that are recommended by NICE through an appraisal should be funded; however, they are not reimbursed until services are commissioned. Payers make their own decisions when commissioning services that lack NICE recommendations.
The Scottish Medicines Consortium (SMC) reviews all pharmaceuticals for use in NHS Scotland, while the Scottish Health Technologies Group (SHTG) provides advice to NHS Scotland regarding medical devices.
UK payers’ primary focus:
Cost effectiveness is the key decision driver in the UK market.
To discuss your UK launch strategy with our experts or to enquire about market research services, get in touch using the form below.
Our work in the UK market
At Mtech Access, we have a network of over 100 Associates who currently hold roles across the UK NHS.
Our unique NHS relationships guide and validate everything we do in the UK.
Here are just a few examples of how we have supported clients launching in the UK market:
Delivering a White Paper to highlight national variation in care, and propose solutions for improving care across the NHS
Understanding the diagnostic market access landscape in the UK
Understanding changing perceptions of value in the NHS
Exploring funding and reimbursement routes for digital health technologies across EU4, UK and US
Researching market access pathways, reimbursement requirements and implications of orphan drug designation for a rare disease product
Gaining global payer insights to inform clinical trial design, price and market access strategy
Reviewing HTA decisions in key markets across the globe
More UK market insights and research
Specialised commissioning continues to be an issue of significance and uncertainty for both the NHS and industry. What do the latest reports of regional pushback on the plans for devolution to Integrated Care Boards (ICBs) mean?
What does it take to run a truly patient-centric integrated health system? What does the Welsh journey with integration tell us about the future for England?
How can the life sciences industries and the healthcare sector work together to deliver real change? Robert Hull (Senior Consultant – NHS Insight & Interaction, Mtech Access) offers an overview of the key themes discussed at our NHS Transformation Symposium.